江苏吴中医药发展股份有限公司 关于公司股票可能被实施重大违法强制退市的第十七次风险提示公告

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure, which may lead to significant penalties and potential delisting of its stock [2][4]. Group 1: Investigation and Regulatory Actions - The company received a notice from the CSRC on July 13, 2025, indicating that it had inflated revenue, costs, and profits in its annual reports from 2020 to 2023, which could trigger mandatory delisting due to serious violations [4][5]. - The company was formally notified of the investigation on February 26, 2025, due to allegations of information disclosure violations [3][4]. Group 2: Financial Irregularities - The inflated figures included revenue increases of CNY 495.26 million, CNY 468.51 million, CNY 430.75 million, and CNY 376.66 million for the years 2020 to 2023, representing 26.46%, 26.39%, 21.26%, and 16.82% of reported revenues respectively [4]. - The inflated costs were CNY 480.68 million, CNY 448.24 million, CNY 410.82 million, and CNY 355.44 million for the same years, accounting for 37.08%, 35.47%, 28.40%, and 20.95% of reported costs respectively [4]. - The total profit inflation was CNY 14.58 million, CNY 20.27 million, CNY 19.92 million, and CNY 21.22 million, which constituted 2.89%, 51.65%, 26.42%, and 29.81% of reported profits respectively [4]. Group 3: Current Risks and Financial Status - The company faces multiple delisting risks, including major violations, financial delisting, and face value delisting, alongside unresolved issues related to significant fund occupation by controlling shareholders [3][6]. - As of the end of 2023, the controlling shareholder's non-operational fund occupation amounted to CNY 1.69 billion, which remains unresolved [6]. - The company reported a net loss of CNY 87.47 million for the first three quarters of 2025, a decline of 294.03% compared to the same period last year [6].